HLN · Pharma and healthcare · one day
Haleon (HLN): news on Monday 2 November 2026
News from the 24 hours to Monday morning, 2 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on Haleon lowering its 2026 organic revenue guidance after third-quarter growth missed expectations, partly offset by a £500m buyback. A positive piece on its AI healthcare appeal did little to change the downbeat lean.
What drove it
- guidance cut
- Q3 growth miss
- £500m buyback
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 27 Oct | +4.2 | 2 |
| Wed 28 Oct | +1.3 | 5 |
| Thu 29 Oct | +5.7 | 5 |
| Fri 30 Oct | −10.0 | 70 |
| Sat 31 Oct | −5.2 | 9 |
| Sun 1 Nov | −3.5 | 2 |
| Mon 2 Nov | −5.7 | 3 |
| Tue 3 Nov | −9.7 | 9 |
2 stories · 3 headlines · strongest first
Pharma and healthcare on 2 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Haleon lowers its 2026 growth outlook following soft third quarter −10.02 headlines today · 60 in all, since 30 October · Reports address the lowered guidance and the £500m share repurchase. | ||
| −9.3 | Weaker quarterly growth than analysts hoped led to a reduced forecast. | |
| −3.0 | Weekly summary pairing a lowered revenue outlook with a sizeable shareholder return programme.}, { | |
| Haleon among British AI healthcare stocks +3.71 headline today · A list piece puts Haleon first among three stocks. | ||
| +3.7 | Company featured as a leading UK healthcare name with AI-related appeal. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated Haleon: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.